Arbutus Biopharma Corporation
ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replicaā¦ read more
Healthcare
Biotechnology
18 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.52
Price-0.88%
-$0.04
1Y
Price
Market Cap
$866.478m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+23.9%
EBITDA Margin+23.5%
Net Profit Margin-146.6%
Free Cash Flow MarginRevenue
$15.416m
+149.8%
1y CAGR+10.1%
3y CAGR+71.4%
5y CAGREarnings
-$54.252m
+22.4%
1y CAGR+7.2%
3y CAGR+7.9%
5y CAGREPS
-$0.28
+26.3%
1y CAGR+14.8%
3y CAGR+20.3%
5y CAGRBook Value
$82.976m
$103.267m
Assets$20.291m
Liabilities$4.999m
DebtDebt to Assets
4.8%
-0.1x
Debt to EBITDAFree Cash Flow
-$60.277m
+7.3%
1y CAGR-36.6%
3y CAGR-15.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company